Articles tagged "HLA antibodies"

2019 American Transplant Congress
Rituximab Desensitization to Liver Transplantaiton Recipients with Preformed Donor Specific Antibodies to Prevent Antibody Mediated Rejecton
Y. Ogura, M. Shizuku, N. Kurata, K. Jobara, H. Kamei
Transplantation Surgery, Nagoya University Hospital, Nagoya City, Japan
*Purpose: Preformed donor-specific antibodies (DSA) are considered as a risk factor after solid organ transplantation. Strong DSA is associated with high mortality and increased risk…
2019 American Transplant Congress
Low Frequency Of Canonical Human Leukocyte Antigen Alloimmunization In Heart Transplantation Candidates With Ventricular Assist Devices
G. K. Mahowald¹, S. L. Saidman¹, G. Lewis², V. Pattanayak¹
¹Pathology, Massachusetts General Hospital, Boston, MA, ²Cardiology, Massachusetts General Hospital, Boston, MA
*Purpose: Screening for anti-HLA antibodies in heart transplantation candidates is complicated by transfusions as well as by the presence of ventricular assist devices (VADs), which…
2019 American Transplant Congress
Early CXCR5⁺PD1⁺ICOS⁺Circulating Follicular T Helpers Are Associated with De Novo Donor-Specific Anti-HLA Antibodies after Renal Transplantation
R. Danger¹, M. Chesneau¹, F. Delbos², S. Lebot¹, C. Kerleau¹, A. Chenouard¹, A. Cesbron², M. Giral³, S. Brouard³
¹CRTI- INSERM UMR 1064- ITUN- Labex IGO -Université de Nantes -CHU Nantes, Nantes, France, ²Laboratoire Histocompatibilité et Immunogénétique - Etablissement Français du sang, Nantes, France, ³Centre d’Investigation Clinique en Biothérapie, Centre de ressources biologiques, Fondation Centaure, CRTI- INSERM UMR 1064- ITUN- Labex IGO -Université de Nantes -CHU Nantes, Nantes, France
*Purpose: Donor specific anti-HLA antibodies (DSA) are a major risk factor associated with renal allograft outcome. As a trigger of B cell antibody production, T…
2019 American Transplant Congress
Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab
Y. kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and is a significant immunologic barrier to graft and patient survival. Pre-transplant desensitization therapy has…
2019 American Transplant Congress
High Prevalence of De Novo Donor-Specific Antibodies during Rejection after Liver Transplantation
J. Colmenero, N. Flores, A. Diaz, M. Vasquez, P. Ruiz, G. Crespo, J. Martorell, M. Navasa
Liver Transplant Unit, Hospital Clinic Barcelona, Barcelona, Spain
*Purpose: Anti-HLA donor specific antibodies (dnDSA) after liver transplantation (LT) are currently under investigation. Recent studies show an incidence of dnDSA after LT ranging from…
2018 American Transplant Congress
Pilot Study of Plasma Cell Niche-Targeted Therapy for Enhancement of Proteasome Inhibitor Effectiveness
S. Tremblay,¹ C. Castro-Rojas,² J. Driscoll,¹ S. Knechtle,³ A. Shields,¹ R. Alloway,¹ H. Singh,² D. Hildeman,² E. Woodle.¹
¹UCincinnati, Cincinnati; ²Cincinnati Children's, Cincinnati; ³Duke, Durham.
HLA antibody (Ab)-secreting bone marrow (BM) plasma cell (PC) survival depends on niche occupancy via a CXCR4 (PC)-CXCL12 (BM stromal cell) interaction. Plerixafor inhibits CXCR4-CXCL12…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients
S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹
¹Nephrology and Transplantation, CHU Hôtel Dieu, Nantes, France; ²Laboratoire HLA, Etablissement Français du Sang, Nantes, France.
Hyperimmunized patients have a bad access to renal transplantation, despite national priority programs and active desensitization protocols. After having noticed that some HLA antibodies decreased…
2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
M. Everly,¹ V. Jucaud,¹ M. Roberts,² H. Gebel,³ R. Bray.³
¹Terasaki Research Institute, Los Angeles, CA; ²Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; ³Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…
2018 American Transplant Congress
Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation
A. Vo, E. Huang, N. Ammerman, S. Williamson, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…